ELAB Stock Overview
Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Elevai Labs, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.71 |
| 52 Week High | US$4.24 |
| 52 Week Low | US$0.57 |
| Beta | 0 |
| 1 Month Change | 2.07% |
| 3 Month Change | 10.84% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -79.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| ELAB | US Personal Products | US Market | |
|---|---|---|---|
| 7D | 22.3% | -1.1% | 2.2% |
| 1Y | n/a | -28.3% | 22.8% |
Return vs Industry: Insufficient data to determine how ELAB performed against the US Personal Products industry.
Return vs Market: Insufficient data to determine how ELAB performed against the US Market.
Price Volatility
| ELAB volatility | |
|---|---|
| ELAB Average Weekly Movement | 12.8% |
| Personal Products Industry Average Movement | 8.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ELAB's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine ELAB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 18 | Jordan Plews | elevaiskincare.com |
Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021.
Elevai Labs, Inc. Fundamentals Summary
| ELAB fundamental statistics | |
|---|---|
| Market cap | US$11.42m |
| Earnings (TTM) | -US$4.30m |
| Revenue (TTM) | US$1.71m |
7.2x
P/S Ratio-2.9x
P/E RatioIs ELAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELAB income statement (TTM) | |
|---|---|
| Revenue | US$1.71m |
| Cost of Revenue | US$578.02k |
| Gross Profit | US$1.13m |
| Other Expenses | US$5.44m |
| Earnings | -US$4.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 66.25% |
| Net Profit Margin | -251.17% |
| Debt/Equity Ratio | 0% |
How did ELAB perform over the long term?
See historical performance and comparison